Literature DB >> 16085759

Despite similar anxiolytic potential, the 5-hydroxytryptamine 2C receptor antagonist SB-242084 [6-chloro-5-methyl-1-[2-(2-methylpyrid-3-yloxy)-pyrid-5-yl carbamoyl] indoline] and chlordiazepoxide produced differential effects on electroencephalogram power spectra.

Sandor Kantor1, Rita Jakus, Eszter Molnar, Norbert Gyongyosi, Attila Toth, Laszlo Detari, Gyorgy Bagdy.   

Abstract

Serious efforts have been made to develop anxiolytics with improved clinical utility and reduced side effects. 5-Hydroxytryptamine (5-HT)(2C) receptor antagonists are potential anxiolytics; however, their effects on vigilance are not well characterized. To compare the effects of benzodiazepines and subtype-selective 5-HT(2C) receptor antagonists on anxiety, vigilance, and electroencephalogram (EEG) power density, social interaction test and polygraphic recordings were performed in male Sprague-Dawley rats after chlordiazepoxide (CDP; 4.0 mg/kg i.p.) and SB-242084 (6-chloro-5-methyl-1-[2-(2-methylpyrid-3-yloxy)-pyrid-5-yl carbamoyl] indoline) (0.1, 0.3, and 1.0 mg/kg i.p.) treatment. CDP and SB-242084 (0.3 and 1.0 mg/kg) had similar anxiolytic effects. Spectral analysis of EEG in wakefulness (W) and paradoxical sleep (PS) showed an opposite effect on activity (5-9 Hz); it decreased after CDP, whereas it increased after SB-242084 (even at 0.1 mg/kg). In addition, CDP significantly decreased slow-wave activity (0.5-4 Hz) in deep slow-wave sleep (SWS-2) and increased power at frequencies above 12 Hz mainly in W and PS. A markedly increased intermediate stage of sleep was also found after CDP treatment. At the highest dose, SB-242084 increased W and decreased SWS-2. In summary, low but potent anxiolytic doses of the subtype-selective 5-HT(2C) receptor antagonist SB-242084 did not affect vigilance states but caused an increased activity in W, raising the possibility of a cognitive-enhancing effect of the drug. In contrast, acute CDP administration, based on spectral analysis of the EEG, produced a more superficial sleep along with a decreased activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16085759     DOI: 10.1124/jpet.105.086413

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment.

Authors:  Szilvia Vas; Zita Kátai; Diána Kostyalik; Dorottya Pap; Eszter Molnár; Péter Petschner; Lajos Kalmár; György Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2012-06-24       Impact factor: 3.575

Review 2.  Serotonergic modulation of hippocampal theta activity in relation to hippocampal information processing.

Authors:  María Esther Olvera-Cortés; Blanca Erika Gutiérrez-Guzmán; Elisa López-Loeza; J Jesús Hernández-Pérez; Miguel Angel López-Vázquez
Journal:  Exp Brain Res       Date:  2013-08-30       Impact factor: 1.972

3.  Control of hippocampal theta rhythm by serotonin: role of 5-HT2c receptors.

Authors:  Elin Sörman; Dannie Wang; Mihaly Hajos; Bernat Kocsis
Journal:  Neuropharmacology       Date:  2011-01-31       Impact factor: 5.250

4.  Chronic escitalopram treatment caused dissociative adaptation in serotonin (5-HT) 2C receptor antagonist-induced effects in REM sleep, wake and theta wave activity.

Authors:  Diána Kostyalik; Zita Kátai; Szilvia Vas; Dorottya Pap; Péter Petschner; Eszter Molnár; István Gyertyán; Lajos Kalmár; László Tóthfalusi; Gyorgy Bagdy
Journal:  Exp Brain Res       Date:  2014-01-07       Impact factor: 1.972

5.  The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys.

Authors:  Daniel F Manvich; Heather L Kimmel; Debra A Cooper; Leonard L Howell
Journal:  J Pharmacol Exp Ther       Date:  2012-06-08       Impact factor: 4.030

6.  Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.

Authors:  Norbert Gyongyosi; Brigitta Balogh; Zita Katai; Eszter Molnar; Rudolf Laufer; Kornelia Tekes; Gyorgy Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2010-01-06       Impact factor: 3.575

7.  S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.

Authors:  Anne Dekeyne; Clotilde Mannoury la Cour; Alain Gobert; Mauricette Brocco; Françoise Lejeune; Florence Serres; Trevor Sharp; Annie Daszuta; Amélie Soumier; Mariusz Papp; Jean-Michel Rivet; Gunnar Flik; Thomas I Cremers; Olivier Muller; Gilbert Lavielle; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2008-06-04       Impact factor: 4.530

Review 8.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

9.  Chronic Paroxetine Treatment Prevents the Emergence of Abnormal Electroencephalogram Oscillations in Huntington's Disease Mice.

Authors:  Sandor Kantor; Janos Varga; Shreya Kulkarni; A Jennifer Morton
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

10.  5-HT2CR blockade in the amygdala conveys analgesic efficacy to SSRIs in a rat model of arthritis pain.

Authors:  Stéphanie Grégoire; Volker Neugebauer
Journal:  Mol Pain       Date:  2013-08-12       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.